Friday, February 22, 2019

Urovant Sciences Gets $100M In Debt Funding

Irvine-based Urovant Sciences, which is developing biopharmaceuticals for treating urologic conditions, said late Friday afternoon that it has entered into a deal for up to $100M in debt financing, from Hercules Cpaital. According to the company, the new funding will go towards ongoing development of its lead compound vibegron, for business development o

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---